Entry Point Capital, LLC Immunovant, Inc. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
A detailed history of Entry Point Capital, LLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 470 shares of IMVT stock, worth $12,929. This represents 0.02% of its overall portfolio holdings.
Number of Shares
470
Previous 2,912
83.86%
Holding current value
$12,929
Previous $94.1 Million
86.81%
% of portfolio
0.02%
Previous 0.08%
Shares
3 transactions
Others Institutions Holding IMVT
# of Institutions
212Shares Held
64.4MCall Options Held
697KPut Options Held
629K-
Vanguard Group Inc Valley Forge, PA6.51MShares$179 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.92MShares$135 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY3.4MShares$93.4 Million1.17% of portfolio
-
Deep Track Capital, LP Greenwich, CT2.88MShares$79.3 Million2.5% of portfolio
-
State Street Corp Boston, MA2.72MShares$74.8 Million0.0% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...